Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 11/20 | 0.72 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.62 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.60 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.59 |
| ▸ | SLCO2A1 | Q92959 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.54 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12640068 | 1.00 | PTGFR (0.72) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL10015887 | 0.94 | PTGFR (0.63) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL13585205 | 0.92 | PTGFR (0.61) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL4246388 | 0.92 | PTGFR (0.61) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL12721121 | 0.92 | PTGFR (0.61) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL4246384 | 0.92 | PTGFR (0.61) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL13585203 | 0.92 | PTGFR (0.61) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL13585407 | 0.92 | PTGFR (0.61) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL13960698 | 0.92 | ABCB11 (0.76) | PTGFRPTGER3ABCB11AKR1C3TBXA2R | |
| SCHEMBL21754423 | 0.87 | PTGFR (0.78) | PTGFRPTGER3ABCB11AKR1C3TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947740-B2 | Bimatoprost crystalline form I | FINETECH PHARMACEUTICAL LTD (IL) | 2011-05-24 | — | — | US | disclosed |
| US-20090163596-A1 | Bimatoprost crystalline form I | FINETECH PHARMACEUTICAL LTD. (IL) | 2009-06-25 | — | — | US | disclosed |
| US-7166730-B2 | Process for the preparation of prostaglandin derivatives | FINE TECH LABORATORIES, LTD (IL) | 2007-01-23 | — | — | US | disclosed |
| US-7166730-B2 | Process for the preparation of prostaglandin derivatives | FINE TECH LABORATORIES, LTD (IL) | 2007-01-23 | — | — | US | disclosed |
| US-20050209337-A1 | Process for the preparation of prostaglandin derivatives | FINETECH LABORATORIES LTD | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209337-A1 | Process for the preparation of prostaglandin derivatives | PTGIS, PTGES, PTGIR | PTGFR 14/4885PTGER3 15/4885ABCB11 3912/4885 |
| US-20090163596-A1 | Bimatoprost crystalline form I | PTGER1, BBC3, CYP2A7 | PTGFR 28/4885PTGER3 14/4885ABCB11 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.